Embecta (NASDAQ:EMBC) Trading Up 4.4% – Still a Buy?

Embecta Corp. (NASDAQ:EMBC) shares traded up 4.4% on Monday . The stock traded as high as $12.72 and last traded at $12.82. 307,456 shares traded hands during trading, a decline of 30% from the average session volume of 439,901 shares. The stock had previously closed at $12.28.

Embecta Price Performance

The business’s fifty day moving average price is $15.02 and its 200-day moving average price is $16.23. The stock has a market capitalization of $727.84 million, a PE ratio of 12.52, a P/E/G ratio of 0.78 and a beta of 1.27.

Embecta (NASDAQ:EMBC) last announced its earnings results on Thursday, February 6th. The company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. On average, analysts expect that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Friday, February 28th were given a dividend of $0.15 per share. The ex-dividend date of this dividend was Friday, February 28th. This represents a $0.60 annualized dividend and a dividend yield of 4.79%. Embecta’s dividend payout ratio (DPR) is presently 60.00%.

Insiders Place Their Bets

In related news, Director Milton Mayo Morris sold 3,100 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $16.38, for a total transaction of $50,778.00. Following the completion of the sale, the director now directly owns 36,133 shares in the company, valued at $591,858.54. This represents a 7.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.42% of the stock is owned by insiders.

Institutional Investors Weigh In On Embecta

A number of large investors have recently added to or reduced their stakes in EMBC. Vanguard Group Inc. boosted its holdings in Embecta by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 7,025,483 shares of the company’s stock valued at $145,076,000 after acquiring an additional 28,031 shares in the last quarter. Deerfield Management Company L.P. Series C increased its position in shares of Embecta by 19.8% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 3,270,535 shares of the company’s stock valued at $67,537,000 after buying an additional 540,192 shares during the period. American Century Companies Inc. lifted its holdings in Embecta by 8.0% in the fourth quarter. American Century Companies Inc. now owns 3,261,934 shares of the company’s stock worth $67,359,000 after buying an additional 242,668 shares during the period. Geode Capital Management LLC grew its holdings in shares of Embecta by 3.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,387,273 shares of the company’s stock worth $19,564,000 after acquiring an additional 45,228 shares during the period. Finally, William Blair Investment Management LLC purchased a new position in shares of Embecta in the 4th quarter valued at approximately $15,270,000. Institutional investors own 93.83% of the company’s stock.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.